Zobrazeno 1 - 10
of 365
pro vyhledávání: '"C, Monneret"'
Autor:
C. MONNERET
Publikováno v:
Médecine et Armées Vol. 45 No.1 ISBN: 9782813004994
La naissance de la chimiothérapie des cancers date de la fin des années 1940, cinq ans après la fin de la Seconde Guerre mondiale. Deux mille bombes chargées d’ypérite sont entreposées dans les cales d’un navire des forces alliées, le John
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e8b380fe9add3a449af9f95babd188b
https://doi.org/10.17184/eac.7456
https://doi.org/10.17184/eac.7456
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 72:229-237
Among the new molecular entities approved by the EMEA and the FDA in 2012, four have caught our attention for their significant contribution to the health of patient. First of all, among the notable 2012 approvals, is ivacaftor or Kalydeco®. This is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fe919657c6f0390ceb608303fd21c8e
https://doi.org/10.1016/j.pharma.2014.03.001
https://doi.org/10.1016/j.pharma.2014.03.001
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 71:95-103
Among the 35 new molecular entities approved by the FDA in 2011, 17 were particularly notable for their significant contributions to the health of patients, including abiraterone acetate, vandetanib, belatacept and fidaxomicin. Thus, abiraterone acet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd0d2dfc91f33e12a2f0e266fb8fdb0
https://doi.org/10.1016/j.pharma.2013.01.004
https://doi.org/10.1016/j.pharma.2013.01.004
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 68:218-232
Resume Au milieu des annees 1990, avec le developpement de la chimie combinatoire et des criblages a haut debit, un moindre interet pour les produits naturels devint perceptible dans l’industrie pharmaceutique. Ce phenomene fut accentue par le fait
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e4431cf3451593ba502b3ab9c4836cf
https://doi.org/10.1016/j.pharma.2010.04.004
https://doi.org/10.1016/j.pharma.2010.04.004
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 68:99-103
Bisphenol A (BPA) is used for the manufacture of polycarbonate plastics and epoxy resin. Since several years it has been reported that BPA belongs to the group of estrogenic xenobiotic or endocrine disruptors (EDC) which are non steroidal substances
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::136b9effa26cad7335a2221f62b07da2
https://doi.org/10.1016/j.pharma.2009.11.002
https://doi.org/10.1016/j.pharma.2009.11.002
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 67:154-157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce8e013f629693f3b5b725821d708a16
https://doi.org/10.1016/j.pharma.2008.12.003
https://doi.org/10.1016/j.pharma.2008.12.003
Autor:
C. Monneret
Publikováno v:
Annales Pharmaceutiques Françaises. 66:212-215
Resume En janvier 2008, apres la mise en evidence des reactions allergiques severes, plusieurs lots d’heparines injectables ont ete retires du marche Etats-Unis. Des tels effets indesirables ont ete egalement observes en Allemagne mais pas en Franc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5585cb358364345be7a6414273267d61
https://doi.org/10.1016/j.pharma.2008.07.004
https://doi.org/10.1016/j.pharma.2008.07.004
Publikováno v:
Annales Pharmaceutiques Françaises. 63:343-349
Resume Pour degrader les proteines, les cellules eucaryotes disposent de deux systemes principaux de degradation que sont le systeme des proteases lysosomales et le systeme du proteasome, ubiquitine et ATP-dependant. Cette derniere voie de degradatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::611efe0acd32e7ab9df9b2f8ae2fd2af
https://doi.org/10.1016/s0003-4509(05)82301-6
https://doi.org/10.1016/s0003-4509(05)82301-6
Publikováno v:
Annales Pharmaceutiques Françaises. 63:53-62
Three glucuronyl prodrugs of paclitaxel have been synthesized in order to be activated by the B-glucuronidase present within the necrotic areas of tumors. As three compartments containing prodrugs, they include a specifier, a self immolative spacer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a07b2f825e27ad39ce3bf46b74fb75f
https://doi.org/10.1016/s0003-4509(05)82251-5
https://doi.org/10.1016/s0003-4509(05)82251-5
Autor:
C, Monneret
Publikováno v:
Annales pharmaceutiques francaises. 72(4)
Among the new molecular entities approved by the EMEA and the FDA in 2012, four have caught our attention for their significant contribution to the health of patient. First of all, among the notable 2012 approvals, is ivacaftor or Kalydeco®. This is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d290732168e37545e822c669ba0e628c
https://pubmed.ncbi.nlm.nih.gov/24997884
https://pubmed.ncbi.nlm.nih.gov/24997884